Alkermes (ALKS)
(Delayed Data from NSDQ)
$27.32 USD
-0.31 (-1.12%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $27.30 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Alkermes (ALKS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$34.69 | $50.00 | $21.00 | 25.55% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Alkermes comes to $34.69. The forecasts range from a low of $21.00 to a high of $50.00. The average price target represents an increase of 25.55% from the last closing price of $27.63.
Analyst Price Targets (13)
Broker Rating
Alkermes currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, eight are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ALKS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.00 | 2.00 | 2.00 | 2.08 | 2.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/25/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
7/25/2024 | H.C. Wainwright & Co. | Douglas Tsao | Hold | Hold |
7/24/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
6/17/2024 | Cowen & Co. | Joseph Thome | Not Available | Strong Buy |
5/23/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
5/1/2024 | SVB Securities | Marc Goodman | Hold | Hold |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
4/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/20/2024 | UBS | Ashwani Verma | Hold | Strong Sell |
10/24/2023 | Evercore Partners | Umer Raffat | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 14 |
Average Target Price | $34.69 |
LT Growth Rate | 20.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | 0.78 |